About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Safety of Gadovist in Renally Impaired Patients | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 4NCT00828737

Safety of Gadovist in Renally Impaired Patients

Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Gadovist, will be asked to participate. The administration...

Lead sponsor: Bayer•70 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Bayer

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with moderate (eGFR 30 - 59 ml/min/173m2) or severe (eGFR \< 30 ml/min/1.73m2) renal impairment, scheduled to undergo Gadovist-enhanced MRI

Exclusion Criteria

•GBCA-enhanced MRI (or administration of a GBCA for any other CE imaging procedure) other than Gadovist within 12 months prior to administration of Gadovist
•History of NSF (Nephrogenic Fibrosing Dermopathy)
•Age outside the indicated age range mentioned in national labelling.

Related studies

RECRUITINGPhase 2

A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis

NCT07417553 · Chronic Hepatitis B-related Liver Fibrosis

Impact of Sinus Surgery on Individuals With Cystic Fibrosis

NCT04469439 · Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis

RECRUITINGPhase 3

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

NCT07357727 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), and more

RECRUITINGPhase 2

Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

NCT04530383 · Cystic Fibrosis-related Diabetes, Cystic Fibrosis

RECRUITINGPhase 1

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

NCT06154447 · Cystic Fibrosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 18, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment927

Start dateDec 2008

Last updatedFeb 18, 2016

Condition

Fibrosis Renal Impairment

Locations shown

Adelaide, South Australia

Clayton, Victoria

Geelong, Victoria

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2016Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions